Reliable, representative, and timely SARS-CoV-2 seroprevalence estimates continue to be important for mapping the trajectory of the COVID-19 pandemic in Kenya, and informing disease control strategies. Including vaccination programs. Serial seroprevalence estimates in general population samples help to inform changes in SARS-CoV-2 cumulative incidence over time and changes in population immunity. Serial sero-surveys can also help identify gaps in population immunity within specific populations to inform targeted interventions, such as targeted vaccination campaigns. Furthermore, they can inform the contribution of vaccination
to population immunity and can be leveraged, within population cohorts, to evaluate the duration of immunity conferred from either natural infection or vaccination.